PatentJun 26, 2026, 07:02 AM
Can-Fite Secures Japan Patent for Namodenoson in Obesity
AI Summary
Can-Fite BioPharma announced that the Japan Patent Office has allowed a patent for its lead drug candidate, Namodenoson, for use in achieving fat loss and treating obesity and related metabolic disorders. This allowance significantly strengthens the company's global intellectual property portfolio in a key pharmaceutical market, building on existing patents in other major jurisdictions. Namodenoson, an orally administered A3 adenosine receptor agonist, offers a differentiated mechanism of action in a global obesity therapeutics market projected to exceed $60 billion by 2030.
Key Highlights
- Japan Patent Office allowed patent for Namodenoson for fat loss and treating obesity.
- Patent covers A3 adenosine receptor agonists, including Namodenoson, for obesity and metabolic disorders.
- Strengthens global intellectual property portfolio, adding to US, Canada, Australia, and Israel patents.
- Namodenoson is an orally administered, highly selective A3AR agonist with an established safety profile.
- Global obesity therapeutics market is expected to exceed $60 billion by 2030.
- Namodenoson is also in Phase 3 for advanced liver cancer and Phase 2b for MASH.
Price Impact
More from CANF